Tag Archives: contingent value right

Sanofi Acquires Vigil Neuroscience to Advance VG-3927 Alzheimer’s Program and Expand Neurodegeneration Research

(IN BRIEF) Sanofi has finalized its takeover of Vigil Neuroscience for roughly $470 million, acquiring all outstanding shares at $8 each and issuing a $2-per-share CVR tied to VG-3927’s first commercial sale. This deal, following Sanofi’s June 2024 strategic investment, … Read the full press release